Novel and emerging drugs for rarer chronic lymphoid leukaemias

Current Cancer Drug Targets

Volumn 12, Issue 5, 2012, Pages 484-504

  Matutes, E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

ATLL; Clinical trial; Hairy cell leukaemia; Immunochemotherapy; LGLL; Prolymphocyte; Purine analogues; Targeted therapy

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ATM PROTEIN; CARBOPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; MITOXANTRONE; MOGAMULIZUMAB; NELARABINE; OFATUMUMAB; PENTOSTATIN; PREDNISOLONE; PREDNISONE; PROTEIN P53; RANIMUSTINE; RITUXIMAB; SIPLIZUMAB; TIPIFARNIB; UNINDEXED DRUG; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ANTIGEN EXPRESSION; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; HAIRY CELL LEUKEMIA; HUMAN; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LEUKEMIA CELL; LOW DRUG DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROLYMPHOCYTIC LEUKEMIA; REVIEW; T CELL LEUKEMIA;

EID: 84861757330     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800673211     Document Type: Review

References (121)

1. Swerdlow, S. H.; Campo, E.; Harris, N. L.; Jaffe, E. S.; Pileri, S. A.; Stein, H.; Thiele, J.; Wardiman, J.W. Eds. WHO classification of tumours of Haematopoietic and lymphoid tissues IARC Lyon, 2008.
2. Robak, T. Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr. Med. Chem. 2009, 16, 2212-2234.
3. Galton, D. A. G.; Goldman, J. M.; Wiltshaw, E.; Catovsky, D.; Henry, K.; Goldenberg, G. J. Prolymphocytic leukaemia. Br. J. Haematol. 1974, 27, 17-23.
4. Dungarwalla, M.; Matutes, E.; Dearden, C. E. Prolymphocytic leukaemia of B and T cell subtype: A state of the art paper. Eur. J. Haematol. 2008, 80, 469-476.
5. Matutes, E.; Attygalle, A.; Wotherspoon, A.; Catovsky, D. Diagnostic issues in chronic lymphocytic leukaemia (CLL). Best Pract. Res. Clin. Haematol. 2010, 23, 3-20.
6. Ruchlemer, R.; Parry-Jones, N.; Brito-Babapulle, V.; Attolico, I.; Wotherspoon, A. C.; Matutes, E.; Catovsky D. B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br. J. Haematol. 2004, 125, 330-336.
7. Lens, D.; de Shouver, P. J.; Hamoudi, R. A.; Abdul-Rauf, M.; Rarahat, N.; Matutes, E.; Dyer, M. J. S.; Catovsky, D. p53 abnormalities in B-cell prolymphocytic leukaemia. Blood 1997, 89, 2015-1023.
8. Del Guidice, I.; Davis, Z.; Matutes, E.; Osuji, N.; Parry-Jones, N.; Morilla, A.; Brito-Babapulle, V.; Oscier, D.; Catovsky, D. IgVH gene mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolyphocytic leukemia (B-PLL). Leukemia 2006, 20, 1231-1237.
9. Del Giudice, I.; Osuji, N.; Dexter, T.; Brito-Babapulle, V.; Parry-Jones, N.; Chiaretti, S.; Messina, M.; Morgan, G.; Catovsky, D.; Matutes, E. B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia 2009, 23, 2160-2167.
10. Shvidel, L.; Shtalrid, M.; Bassous, L.; Klepfish, A.; Vorst, E.; Berrebi, A. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk. Lymphoma 1999, 33, 169-179.
11. Hercher, C.; Robain, M.; Davi, F.; Garand, R.; Flandrin, G.; Valensi, F.; Vandeputte, H.; Albert, A.; Maynadie, M.; Troussard, X.; Simon, G. H.; Lespinasse, J.; Portefaix, G.; Merle-Beral, H.; Groupe Francais d́Hematologie Cellulaire. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk. Lymphoma 2001, 45, 981-987.
12. Robak, T.; Robak, P. Current treatment options in prolymphocytic leukemia. Med. Sci. Monit. 2007, 13, 69-80.
13. Kantarjian, H. M.; Childs, C.; ÓBrien, S.; Huh, Y.; Beran, M.; Schachner, J.; Koller, C.; Keating, M. J. Efficacy of fludarabine, a new adenosine nucleoside analogue in patients with prolymphocytic leukaemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am. J. Med. 1991, 90, 223-228.
14. Dohner, H.; Ho, A. D.; Thaler, J.; Stryckmans, P.; Sonneveld, P.; de Witte, T.; Lechner, K.; Lauria, F.; Bodewadt-Radzun, S.; Suciu, S. Pentostatin in prolymphocytic leukemia: phase II trial of the European Organizatin for Research and Treatment of Cancer Leukemia Cooperative group. J. Natl. Cancer Inst. 1993, 85, 658-662.
15. Saven, A.; Lee, T.; Schltz, M.; Jacobs, A.; Ellison, D.; Longmire, R.; De Braekeleer, M.; Berthou, C. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J. Clin. Oncol. 1997, 15, 37-43.
16. Bowen, A. L.; Zomas, A.; Emmett, E.; Matutes, E.; Dyer, M. J.; Catovsky, D. Subcutaneous Campath-1H in fludarabine resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. Haematol. 1997, 96, 617-619.
17. Mourad, Y. A.; Taher, A.; Chehal, A.; Shamseddine, A. Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann. Hematol. 2004, 83, 319-321.
18. Ginaldi, L.; De Martinis, M.; Matutes, E.; Farahat, N.; Morilla, R.; Catovsky, D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J. Clin. Path. 1998, 51, 364-369.
19. Chow, K. U.; Kim, S. Z.; von Neuhoff, N; Schlegelberger, B; Stilgenbauer, S; Wnderle, L; Cordes, H. J; Bergmann, L. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur. J. Haematol. 2011, 87 (5), 426-433
20. Shvidel, L.; Shtalrid, M.; Klepfish, A.; Haran, M.; Berrebi A. Successful autologous stem cell transplantation in aggressive prolymphocytic leukaemia. Am. J. Hematol. 2000, 63, 230-231.
21. Castagna, L.; Sarina, B.; Todisco, E.; Mazza, R.; Santoro, A. Allogeneic peripheral stem-cell transplantation with reduced intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. Bone Marrow Transplantation 2005, 35, 1225.
22. Kalaycio, M. E.; Kukreja, M.; Woolfrey, A. E.; Szer, J.; Cortes, J.; Maziarz, R. T.; Bolwell, B. J.; Buser, A.; Copelan, E.; Gale, R. P.; Gupta, V.; Maharaj, D.; Marks, D. I.; Pauletic, S. Z.; Horowitz, M. M.; Arora, M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol. Blood Marrow Transplant. 2010, 16, 543-547.
23. Bouroncle, B. A.; Wiseman, B. K.; Doen, C. A. Leukemic reticuloendotheliosis. Blood 1958, 13, 609-630.
24. Matutes, E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol. Oncol. Clin. North Am. 2006, 20, 1051-1063.
25. Hockley, S.; Morgan, G. J.; Leone, P. E.; Walker, B. A.; Morilla, A.; Else, M.; Wotherspoon, A.; Dearden, C.; Catovsky, D.; Gonzalez, D.; Matutes, E. High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia. Leukemia 2011, 25, 1189-1192.
26. Hockley, S. L.; Giannouli, S.; Morilla, A.; Wotherspoon, A.; Morgan, G. J.; Matutes, E.; Gonzalez, D. Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br. J. Haematol. 2010, 148, 666-669.
27. Tiacci, E.; Trifonov, V.; Schiavoni, G.; Holmes, A.; Kern, W.; Martelli, M. P.; Pucciarini, A.; Bigerna, B.; Pacini, R.; Wells, V. A.; Sportoletti, P.; Pettirossi, V.; Mannucci, R.; Elliott, O.; Liso, A.; Ambrosetti, A.; Pulsoni, A.; Forconi, F.; Trentin, L.; Semenzato, G.; Inghirami, G.; Capponi, M.; Di Raimondo, F.; Patti, C.; Arcaini, L.; Musto, P.; Pileri, S.; Haferlach, C.; Schnittger, S.; Pizzolo, G.; Foa, R.; Farinelli, L.; Haferlach, T.; Pasqualucci, L.; Rabadan, R.; Falini, B. BRAF mutations in hairycell leukemia. N. Engl. J. Med. 2011, 364, 2305-2315.
28. Mercieca, J.; Puga, M.; Matutes, E.; Moskovic, E.; Salin, S.; Catovsky, D. Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. Leuk. Lymphoma 1994, 14 suppl. 1, 79-83.
29. Arons, E.; Suntum, T.; Stetler-Stevenso, M.; Kreitman, R.J. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009, 114, 4687-4695.
30. Quesada, J. R.; Reuben, J.; Manning, J. T.; Hersh, E. M.; Gutterman, J. U. Alpha interferon for induction of remission in hairy cell leukemia. N. Engl. J. Med. 1984, 310, 15-18.
31. Grever, M.; Kopecky, K.; Foucar, M. K.; Head, D.; Bennett, J. M.; Hutchinson, R. E.; Corbett, W. E.; Cassileth, P. A.; Habermann, T.; Golomb, H. Randomized comparison of pentostatin versus interferon alpha in previously untreated patients with hairy cell leukemia: An intergroup study. J. Clin. Oncol. 1995, 13, 974-982.
32. Golomb, H. M. Hairy cell leukaemia. Treatment successes in the past 25 years. J. Clin. Oncol. 2008, 26, 2607-2609.
33. Spiers, A. S.; Parekh, S. L.; Bishop, M. B. Hairy cell leukaemia: induction of complete remission with pentostatin (2'-deoxycoformycin). J. Clin. Oncol. 1984, 2, 1336-1342.
34. Piro, L. D.; Carrera, C. J.; Carson, D. A.; Beutler, E. Lasting remissions in hairy cell leucemia induced by a single infusión of 2-chlorodeoxyadenosine. N. Engl. J. Med. 1990, 322, 1117-1121.
35. Cheson, B. D.; Sorensen, J. M.; Montello, M. J.; Barrett, J. A.; Damasio, E.; Tallman, M.; Anino, L.; Connors, J.; Coiffier, B.; Lauria, F. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J. Clin. Oncol. 1998, 16, 3007-3015.
36. Goodman, R. G.; Burian, C.; Koziol, J. A.; Saven, A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J. Clin. Oncol. 2003, 21, 891-896.
37. Jeh, U.; Barti, R.; Dietzfelbinger, H.; Haferlach, T.; Heinemann, V. An update: 12 year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004, 18, 1476-1481.
38. Rafel, M.; Cervantes, F.; Beltran, J. M.; Zuazu, F.; Hernandez-Nieto, L.; Garcia-Talavera, J.; Montserrat, E. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a spanish collaborative study in 80 patients. Cancer 2000, 88, 352-357.
39. Chadha, P.; Rademaker, A. W.; Mendiratta, P.; Kim, B.; Evanchuck, D. M.; Hakimian, D.; Peterson, L. C.; Tallman, M. S. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine: long term follow-up of the Northwestern University experience. Blood 2005, 106, 241-246.
40. Else, M.; Dearden, C. E.; Matutes, E.; Garcia-Talavera, J.; Rohatiner, A. Z.; Johnson, S. A.; ÓConnor, N. T.; Haynes, A.; Osuji, N.; Forconi, F.; Lauria, F.; Catovsky, D. Long-term followup of 233 patients with hairy cell leukaemia treated initially with pentostatin or cladribine at a median of 16 years. Br. J. Haematol. 2009, 145, 733-740.
41. Mercieca, J.; Matutes, E.; Emmett, E.; Coles, H.; Catovsky, D. 2 Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br. J. Haematol. 1996, 93, 409-411.
42. Lauria, F.; Lenoci, M.; Annino, L.; Raspadori, D.; Marotta, G.; Bocchia, M.; Gentili, S.; La Manda, M.; Marconcini, S.; Tozzi, M.; Baldini, L.; Zinzani, P. L.; Foa, R. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukaemia. Haematologica 2001, 86, 1046-1050.
43. Nieva, J.; Bethel, K.; Saven, A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia. Blood 2003, 102, 810-813.
44. Else, M.; Osuji, N.; Forconi, F.; Dearden, C. E.; Del Giudice, I.; Matutes, E.; Wotherspoon, A.; Lauria, F.; Catovsky D. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukaemia. Cancer 2007, 110, 2240-2247.
45. Kreitman, R. J. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009, 23, 1-13.
46. Kreitman, R. J.; Pastan, I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol. Oncol. Clin. North Am. 2006, 20, 1137-1151.
47. Kreitman, R. J.; Squires, D. R.; Stetler-Stevenson, M.; Noel, P.; Fitzgerald, D. J.; Wilson, W. H.; Pastan, I. Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. 2005, 23, 6719-6729.
48. Kreitman, R. J.; Squires, D. R.; Stetler-Stevenson, M.; Noel, P.; Fitzgerald, D. J.; Wilson, W. H.; Pastan, I. Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leucemia. J. Clin. Oncol. 2009, 27, 293-2990.
49. Bang, S.; Nagata, S.; Onda, M.; Kreitman, R. J.; Pastan, I. HA22 (R490A) is a recombinant immunotoxin with increased antitumour activity without an increase in animal toxicity. Clin. Cancer Res. 2005, 11, 1545-1550.
50. Kreitman, R. J.; Tallman, M. S.; Robak, T.; Coutre S; Wilson, W. H.; Stetler-Stevenson, M.; Noel, P; Fitzerald, D. J.; Lechleider, R; Pastan, I. Phase I trial of anti-CD22 recombinant immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 2012, Feb 21 (Epub ahead of print)
51. Grever, M. R.; Lozanski, G. Modern strategies for hairy cell leukemia. J. Clin. Oncol. 2011, 29, 583-590.
52. Matutes, E.; Wotherspoon, A.; Catovsky, D. The variant form of hairy cell leukaemia. Best Pract. Res. Clin. Haematol. 2003, 16, 41-56.
53. Matutes, E.; Wotherspoon, A.; Brito-Babapulle, V.; Catovsky, D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001, 15, 184-186.
54. Robak, T. Hairy cell leukemia variant: Recent view on diagnosis, biology and treatment. Cancer Treat. Rev. 2011, 37, 3-10.
55. Sgarabotto, D.; Vianello, F.; Radsossi, P.; Poletti, A.; Sotti, G.; Stefani, P. M.; Sartori, R.; Girolami, A. Remission in hairy cell leukemia-variant following splenic irradiation alone. Leuk. Lymphoma 1997, 26, 395-398.
56. Sasaki, M.; Sugimoto, K.; Mori, T.; Karasawa, K.; Oshimi, K. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Acta Haematol. 2008, 119, 48-53.
57. Sainati, L.; Matutes, E.; Mulligan, S.; de Oliveira, M. P.; Rani, S.; Lampert, I. A.; Catovsky, D. Variant form of hairy cell leukemia resistant to interferon-alpha: clinical and phenotypic characteristics of 17 patients. Blood 1990, 76, 157-162.
58. Blasinska-Morawiec, M.; Robak, T.; Krykowski, E.; Hellmann, A.; Urbanska-Rys, H. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine-a report of three cases. Leuk. Lymphoma 1997, 25, 381-185.
59. Tetreault, S. A.; Robbins, B. A.; Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk. Lymphoma 1999, 35, 347-354.
60. Palomera, L.; Domingo, J. M.; Sola, C.; Azaceta, G.; Calvo, M. T.; Rodriguez, M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica 2002, 87, 107-108.
61. Narat, S.; Gandia, J.; Dogan, A.; Mehta, A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk. Lymphoma 2005, 46, 1229-1232.
62. Quach, H.; Januszewicz, H.; Westerman, D. Complete remission of hairy cell leukemia variant (HCL-v) complicated with red cell aplasia post treatment with rituximab. Haematologica 2005, 90, suppl:EO CR26.
63. Telek, B.; Batar, P.; Udvardy, M. Successful alemtuzumab treatment of a patient with atypical hairy cell leukaemia variant. Orv. Hetil. 2007, 148, 1805-1807.
64. Kreitman, R. J.; Wilson, W. H.; Bergeron, K.; Raggio, M.; Stetler-Stevenson, M.; Fitzgerald, D. J.; Pastan, I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy cell leukemia. N. Engl. J. Med. 2001, 345, 241-247.
65. Matutes, E.; Brito-Babapulle, V.; Swansbury, J.; Ellis, J.; Morilla, R.; Dearden, C.; Sempere, A.; Catovsky, D. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991, 78, 3269-3274.
66. Ginaldi, L.; De Martinis, M.; Matutes, E.; Farahat, N.; Morilla, R.; Dyer, M. J. S.; Catovsky, D. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to CAMPATH-1H. Leuk. Res. 1998, 22, 185-191.
67. Bradshaw, P. S.; Condie, A.; Matutes, E.; Catovsky, D.; Yuille, M. R. Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif. Oncogene 2002, 21, 483-487.
68. Durig, J.; Bug, S.; Klein-Hitpass, L.; Boes, T.; Jons, T.; Martin-Subero, J. I.; Harder, L.; Baudis, M. Duhrsen, U.; Siebert, R. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosome imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11;q32). Leukemia 2007, 21, 2153-2163.
69. Herling, M.; Teitell, M. A.; Konopleva, M.; Ravandi, F.; Kobayashi, R.; Jones, D. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 2008, 111, 328-337.
70. Mercieca, J.; Matutes, E.; Dearden, C.; MacLennan, K.; Catovsky, D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 1994, 12, 2588-2593.
71. Dearden, C. E. D.; Matutes, E.; Cazin, B.; Tjonnfjord, G. E.; Parreira, A.; Nomdedeu, B.; Leoni, P.; Clark, F. J.; Radia, D.; Rassam, S. M.; Roques, T.; Ketterer, N.; Brito-Babapulle, V.; Dyer, M. J.; Catovsky, D. High remission rate in T-cell prolyphocytic leukemia with Campath-1H. Blood 2001, 98, 1721-1726.
72. Keating, M. J.; Cazin, B.; Coutre, S.; Birhiray, R.; Kovacsovics, T.; Langer, W.; Leber, B.; Maughan, T.; Rai, K.; Tjonnfjord, G.; Bekradda, M.; Itzhaki, M.; Herait, P. Campath 1H treatment of Tcell prolymphocytic leukemia in patients from whom at least one prior chemotherapy regimen has failed. J. Clin. Oncol. 2002, 20, 205-213.
73. Dearden, C. E. D.; Khot, A.; Else, M.; Hamblin, M.; Grand, E.; Roy, A.; Hemawana, S.; Matutes, E.; Catovsky, D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 2011, 118 (22), 5799-5802
74. Hopfinger, G.; Kandler, G.; Koller, E.; Busch, R.; Eichhorst, B.; Cramer, P.; Kandler, G.; Fingerle-Rowson, G.; Fink, A. M.; Stilgenbauer, S.; Hallek M. T-PLL 1 protocol of the German CLL Study Group (GCLLSG)-A prospective phase 2 trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FCM) followed by alemtuzumab consolidation as first line treatment in T-PLL. Blood 2007, 106, 607 (2130 abstract).
75. Krishnan, B.; Else, M.; Tjonnfjord, G.E.; Cazin, B.; Carney, D.; Carter, J.; Ketterer, N.; Catovsky, D.; Ethell, M.; Matutes, E.; Dearden, C.E. Stem cell transplantation after alemtuzumab in Tcell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br. J. Haematol. 2010, 149, 907-910.
76. Weston, V. J.; Oldreive, C. E.; Skowronska, A.; Oscier, D. G.; Pratt, G.; Dyer, M. J. S.; Smith, G.; Powell, J. E.; Rudzki, Z.; Kearms, P.; Moss, P. A. H.; Taylor, A. M. R.; Stankovic, T. The PARP inhibitor olaparib induces significant killing of ATM deficient lymphoid tumour cells in vitro and in vivo. Blood 2010, 116, 4578-4587.
77. Gandhi, V.; Tam, C.; O'Brien, S.; Jewell, R. C.; Rodriguez, C.O. Jr.; Lemer, S.; Plunkett, W.; Keating, M. J. Phase I trial of nelarabine in indolent leukemias. J. Clin. Oncol., 2008, 26,1098-1105.
78. Loughran, T. P. Jr. Clonal diseases of large granular lymphocytes. Blood 1993, 82, 1-14.
79. Sokol, L.; Loughran, T. P. Jr. Large granular lymphocyte leukemia. Oncologist, 2006, 11, 263-273.
80. Alekshun, T. J.; Sokol, L. Diseases of large granular lymphocytes. Cancer Control 2007, 14, 141-150.
81. Matutes, E. Immunological and clinical features of T-cell LGL disorders. In: Hematology Education: The Education Programme for the Annual Congress of the European Hematology Association, Berlin, Germany 2009, 3, 302-307.
82. Sabnani, I.; Tsang, P. Are clonal T-cell large granular lymphocytes to blame for unexplained haematological abnormalities?. Br. J. Haematol. 2006, 136, 30-37.
83. Starkebaum, G.; Loughran, T. P. Jr.; Gaur, L. K.; Davis, P.; Nepon, B. S. Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansion of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1997, 40, 624-626.
84. Yang, J.; Epling-Burnette, P. K.; Painter, J. S.; Zou, J.; Bai, F.; Wei, S.; Loughran, T. P. Jr. Antigen activation and impaired Fasinduced death-inducing signalling complex formation in T-large granular lymphocyte leukemia. Blood 2008, 111, 1610-1616.
85. Shah, M. V.; Zhang, R.; Irby, R.; Kothapalli, R.; Liu, X.; Arrington, T.; Frank, B.; Lee, N. H.; Loughran, T. P. Jr. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008, 112, 770-781.
86. Epling-Burnette, P. K.; Loughran, T. P. Jr. Survival signals in leukemic large granular lymphocytes. Semin. Hematol. 2003, 40, 213-220.
87. Rodriguez-Caballero, A.; Garcia-Montero, A. C.; Barcena, P.; Almeida, J.; Ruiz-Cabello, F.; Tabernero, M. D.; Garrido, P.; Muñoz-Criado, S.; Sandberg, Y.; Langerak, A. W.; Gonzalez, M.; Balan-zategui, A.; Orfao, A. Expanded cells in monoclonal TCRab+/CD4+/Nka+/CD8-/+dim T-LGL lymphocytes recognize hCMV antigens. Blood 2008, 112, 4609-4616.
88. Garrido, P.; Ruiz-Cabello, F.; Barcena, P.; Sandberg, Y.; Canton, J.; Lima, M.; Balanzategui, A.; Gonzalez, M.; Lopez-Nerot, A. M.; Langerak, A. W.; Garcia-Montero, A. C.; Almeida, J.; Orfao, A. Monoclonal TCR-Vbeta 13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood 2007, 109, 4890-4898.
89. Matutes, E.; Wotherspoon, A. C.; Parker, N. E.; Osuji, N.; Isaacson, P. G.; Catovsky, D. Transformation of T-cell large granular lymphocyte leukemia into a high-grade large T-cell lymphoma. Br. J. Haematol. 2001, 115, 801-806.
90. Loughran, T. P. Jr.; Kidd, P. G.; Starkebaum, G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994, 84, 2164-2170.
91. Osuji, N.; Matutes, E.; Tjonnfjord, G.; Grech, H.; Del Giudice, I.; Wotherspoon, A.; Swansbury, J. G.; Catovsky, D. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. Cancer 2006, 107, 570-578.
92. Subbiah, V.; Viny, A. D.; Rosenblatt, S.; Pohlman, B.; Lichtin, A.; Maciejewski, J. P. Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenias. Exp. Hematol. 2008, 36, 1078-1083.
93. Tsirigotis, P.; Venetis, E.; Kapsimali, V.; Rontogianni, D.; Varvitsioti, E.; Pappa, V.; Apostolidis, P. 2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia. Leuk. Res. 2003, 27, 865-867.
94. Fortune, A. F.; Kelly, K.; Sargent, J.; ÓBrien, D.; Quinn, F.; Chadwick, N.; Flynn, C.; Coneally, E.; Browne, P.; Crotty, G. M.; Thornton, P.; Vandenberghe, E. Large granular lymphocyte leukemia: natural history and response to treatment. Leuk. Lymphoma 2010, 51, 839-845.
95. Sternberg, A.; Eagleton, H.; Pillai, N.; Leyden, K.; Turner, S.; Pearson, D.; Littlewood, T.; Hatton, C. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukemia responds to fludarabine with minimal toxicity. Br. J. Haematol. 2003, 120, 699-701.
96. Tse, E.; Chan, J. C.; Pang, A.; Au, W. Y.; Leung, A. Y.; Lam, C. C.; Kwong, Y. L. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. Leukemia 2007, 21, 2225-2226.
97. Osuji, N.; Del Giudice, I.; Matutes, E.; Morilla, A.; Owusu-Ankomah, K.; Morilla, R.; Dunlop, A.; Catovsky, D. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab. Leuk. Lymphoma 2005, 46, 723-727.
98. ÓMahony, D.; Morris, J. C.; Stetler-Stevenson, M.; Matthews, H.; Brown, M. R.; Fleisher, T.; Pitaluga, S.; Raffeld, M.; Albert, P. S.; Reitsma, D.; Kaucic, K.; Hammershaimb, L.; Waldmann, T. A.; Janik, J. E. EBV related lymphoprolipherative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin. Cancer Res. 2009, 15, 2514-2522.
99. Epling-Burnette, P. K.; Sokol, L.; Chen, X.; Bai, F.; Zhou, J.; Blaskovich, M. A.; Zou, J. X.; Painter, J. S.; Edwards, T. D.; Moscinski, L.; Yoder, J. A.; Djeu, J. Y.; Sebti, S.; Loughran, T. P. Jr.; Wei, S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood 2008, 112, 4694-4698.
100. Shimoyama, M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-1987). Br. J. Haematol. 1991, 79, 428-437.
101. Tsukasaki, K.; Hermine, O.; Bazarbachi, A.; Ratner, L.; Ramos J. C.; Harrington, W. Jr.; ÓMahony, D.; Janik, J. E.; Bittencourt, A. L.; Taylor, G. P.; Yamaguchi, K.; Utsunomiya, A.; Tobinai, K.; Watanabe, T. Definition, prognostic factors, treatment and response criteria of adult T-cell leukemia-Lymphoma: a proposal from an International Consensus Meeting. J. Clin. Oncol. 2009, 20, 453-459.
102. Tsukasaki, K.; Utsunomiya, A.; Fukuda, H.; Shibata, T.; Fukushima, T.; Takatsuka, Y.; Ikeda, S.; Masuda, M.; Nagoshi, H.; Ueda, R.; Tamura, K.; Sano, M.; Momita, S.; Yamaguchi, K.; Kawano, F.; Hanada, S.; Tobinai, K.; Shimoyama, M.; Hotta, T.; Tomonaga, M.; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult Tcell leukemia-lymphoma: Japan Clinical Oncology Group Study. J. Clin. Oncol., 2007, 25, 5458-5464.
103. Waldmann, T. A.; White, J. D.; Goldman, C. K.; Top, L.; Grant, A.; Bamford, R.; Roessler, E.; Horak, I. D.; Zaknoen, S.; Kasten-Sportes, C. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I induced adult T-cell leukemia. Blood, 1993, 82, 1701-1712.
104. Waldmann, T. A.; White, J. D.; Carrasquillo, J. A.; Reynolds, J. C.; Paik, C. H.; Gansow, O. A.; Brechbiel, M. W.; Jaffe, E. S.; Fleisher, T. A.; Goldman, C. K.; Top, L. E.; Bamford, R.; Zaknoen, E.; Roessler, E.; Kasten-Sportes, C.; England, R.; Litou, H.; Johnson, J. A.; Jackson-White, T.; Manns, A.; Hanchard, B.; Junghans, R. P.; Nelson, D. L. Radioimmunotherapy of interleukin-2R alpha expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood, 1995, 86, 4063-4075.
105. Simpson, S.; Thanigaikumar, M.; Taylor, G.; Matutes, E.; Fields, P.; Devereux, S.; Ho, A.; Mufty, G. J.; Pagliuca, A. Combination chemotherapy with CHOP-Daclizumab in HTLV-1 associated adult T-cell leukaemia/lymphoma. Blood, 2006, 108, 778, (2750 abstract).
106. Ravandi, F.; Faderl, S. Complete response in a patient with adult Tcell leukemia (ATLL) treated with a combination of alemtuzumab and pentostatin. Leuk. Res., 2006, 30, 103-105.
107. Gill, P. S.; Harrington, W. Jr.; Kaplan, M. H.; Ribeiro, R. C.; Bennett, J. M.; Liebman, H. A.; Bernstein-Singer, M.; Espina, B. M.; Cabral, L.; Allen, S. Treatment of adult T-cell leukemialymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med., 1995, 332, 1744-1748.
108. Hermine, O.; Bouscary, D.; Gessain, A.; Turlure, P.; Leblond, V.; Franck, N.; Buzyn-Veil, A.; Rio, B.; Macintyre, E.; Dreyfus, F. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med., 1995, 332, 1749-1751.
109. Hermine, O.; Allard, I.; Levy, V.; Gessain, A.; Bazarbachi, A. French ATL therapy Group. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol. J. 2002, 3, 276-282.
110. Matutes, E.; Taylor, G. P.; Cavenagh, J.; Pagliuca, A.; Bareford, D.; Domingo, A.; Hamblin, M.; Kelsey, S.; Mir, N.; Reilly, J. T. Interferon alpha and Zidovudine therapy in adult T-cel leukaemia lymphoma: response and outcome in 15 patients. Br. J. Haematol. 2001, 113, 779-784.
111. Bazarbachi, A.; Plumelle, Y.; Carlos Ramos, J.; Tortevoye, P.; Otrock, Z.; Taylor, G.; Gessain, A.; Harrington, W.; Panelatti, G.; Hermine, O. Meta-analysis on the use of zidovudine and interferonalfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 2010, 28, 4177-4183.
112. Hodson, A.; Chrichton, S.; Montoto, S.; Mir, N.; Matutes, E.; Cwynarski, K.; Kumaran, T.; Ardeshna, K.; Kumaran, T.; Pagliuca, A.; Taylor, G.; Filds, P. Use of Zidovudine and Interferon alpha with chemotherapy improves overall survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma (ATLL). J. Clin. Oncol. 2011 inpress.
113. Datta, A.; Bellon, M.; Sinha-Datta, U.; Bazarbachi, A.; Lepelletier, Y.; Canioni, D.; Waldmann, T. A.; Hermine, O.; Nicot, C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006, 108, 1021-1029.
114. Ishitsuka, K.; Suzumiya, J.; Aoki, M.; Ogata, K.; Hara, S.; Tamura, K. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica 2007, 92, 719-720.
115. Hermine, O.; Dombret, H.; Poupon, J.; Arnulf, B.; Lefrere, F.; Rousselot, P.; Damaj, G.; Delarue, R.; Frenand, J. P.; Brouet, J. C.; Degos, L.; de The, H.; Bazarbachi, A. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol. J. 2004, 5, 130-134.
116. Kchour, G.; Tarhini, M.; Kooshyar, M. M.; El Haji, H.; Wattel, E.; Mahmoudi, M.; Hatoum, H.; Rahimi, H.; Maleki, M.; Rafatpanah, H.; Rezaee, S. A.; Yazdi, M. T.; Shirdel, A.; de The, H.; Hermine, O.; Farid, R.; Bazarbachi, A. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma. Blood 2009, 113, 6528-6532.
117. Yamamoto, K.; Utsunomiya, A.; Tobinai, K.; Tsukasaki, K.; Uike, N.; Uozumi, K.; Yamaguchi, K.; Yamada, Y.; Hanada, S.; Tamura, K.; Nakamura, S.; Inagaki, H.; Ohshima, K.; Kiyoi, H.; Ishida, T.; Matsushima, K.; Akinaga, S.; Ogura, M.; Tomonaga, M.; Ueda, R. Phase I study of KW-0761, a defucosylated humanised anti-CCR4 antibody in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 2010, 28, 1591-1598.
118. Ju, W.; Zhang, M.; Jiang, J-k.; Thomas, C. J.; Oh, U.; Bryant, B. R.; Chen, J.; Sato, N.; Tagaya, Y.; Morris, J. C.; Janik, J. E.; Jacobson, S.; Waldmann, T. A. CP-690,550, a therapeutic agent, inhibits cytokine mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 2011, 117, 1938-1946.
119. Hishizawa, M.; Kanda, J.; Utsinomiya, A.; Taniguchi, S.; Eto, T.; Moriuchi, Y.; Tanosaki, R.; Kawano, F.; Miyazaki, Y.; Masuda, M.; Nagafuji, K.; Hara, M.; Takanashi, M.; Kai, S.; Atsuta, Y.; Suzuki, R.; Kawase, T.; Matsuo, K.; Nagamura-Inoue, T.; Kato, S.; Sakamaki, H.; Morishima, Y.; Okamura, J.; Ichinohe, T.; Uchiyama, T. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116, 1369-1376.
120. Tanosaki, R.; Tobinai, K. Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches. Expert. Rev. Hematol. 2010, 3, 743-753.
121. Tobinai, K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Semin. Hematol. 2010, 47 (suppl 1), S5-7.